Thrita

Published by: Kowsar

The Methylation Status of MGMT and SFRP2 Genes in Iranian Patients With Polyps

Pooneh Mokarram 1 , * , Nazanin Zare 2 , Hamed Jafari 3 , Soudabeh Kavousi Pour 4 , Mahdi Barazesh 4 and Mahvash Alizade Naini 5
Authors Information
1 Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Biochemistry, Science and Research Branch, Islamic Azad University, Shiraz, IR Iran
3 School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 School of Advanced Medical Science and Technologies, Shiraz University of Medical Sciences, Shiraz, IR Iran
5 Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Thrita: June 27, 2015, 4 (2); e28601
  • Published Online: June 20, 2015
  • Article Type: Research Article
  • Received: March 10, 2015
  • Accepted: April 14, 2015
  • DOI: 10.5812/thrita.28601v2

To Cite: Mokarram P, Zare N, Jafari H, Kavousi Pour S, Barazesh M, et al. The Methylation Status of MGMT and SFRP2 Genes in Iranian Patients With Polyps, Thrita. 2015 ;4(2):e28601. doi: 10.5812/thrita.28601v2.

Abstract
Copyright © 2015, Thrita. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. World Cancer Report 2014. 2014;
  • 2. Kim KM, Lee EJ, Ha S, Kang SY, Jang KT, Park CK, et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol. 2011; 35(9): 1274-86[DOI][PubMed]
  • 3. Pap Z, Pavai Z, Denes L, Brinzaniuc K, Jung I. Hyperplastic polyps and serrated adenomas: precancerous lesions with mixed immunophenotype. Rom J Morphol Embryol. 2011; 52(3): 797-802[PubMed]
  • 4. Kaz A, Kim YH, Dzieciatkowski S, Lynch H, Watson P, Kay Washington M, et al. Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas. Int J Cancer. 2007; 120(9): 1922-9[DOI][PubMed]
  • 5. Cassinotti E, Melson J, Liggett T, Melnikov A, Yi Q, Replogle C, et al. DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer. 2012; 131(5): 1153-7[DOI][PubMed]
  • 6. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int. 2011; 2011: 902674[DOI][PubMed]
  • 7. Liljegren A, Lindblom A, Rotstein S, Nilsson B, Rubio C, Jaramillo E. Prevalence and incidence of hyperplastic polyps and adenomas in familial colorectal cancer: correlation between the two types of colon polyps. Gut. 2003; 52(8): 1140-7[PubMed]
  • 8. Schmid G. The use of molecular markers in the diagnosis of colorectal cancer screening. Dig Dis. 2010; 28(4-5): 625-8[DOI][PubMed]
  • 9. Grady WM. Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans. 2005; 33: 684-8[DOI][PubMed]
  • 10. Belshaw NJ, Elliott GO, Foxall RJ, Dainty JR, Pal N, Coupe A, et al. Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer. 2008; 99(1): 136-42[DOI][PubMed]
  • 11. Shah R, Jones E, Vidart V, Kuppen PJ, Conti JA, Francis NK. Biomarkers for early detection of colorectal cancer and polyps: systematic review. Cancer Epidemiol Biomarkers Prev. 2014; 23(9): 1712-28[DOI][PubMed]
  • 12. Belshaw NJ, Pal N, Tapp HS, Dainty JR, Lewis MP, Williams MR, et al. Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa. Carcinogenesis. 2010; 31(6): 1158-63[DOI][PubMed]
  • 13. Sui C, Wang G, Chen Q, Ma J. Variation risks of SFRP2 hypermethylation between precancerous disease and colorectal cancer. Tumour Biol. 2014; 35(10): 10457-65[DOI][PubMed]
  • 14. Matsubara N. Epigenetic regulation and colorectal cancer. Dis Colon Rectum. 2012; 55(1): 96-104[DOI][PubMed]
  • 15. Pehlivan S, Artac M, Sever T, Bozcuk H, Kilincarslan C, Pehlivan M. Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. Cancer Genet Cytogenet. 2010; 201(2): 128-32[DOI][PubMed]
  • 16. Mokarram P, Zamani M, Kavousipour S, Naghibalhossaini F, Irajie C, Moradi Sarabi M, et al. Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer. Mol Biol Rep. 2013; 40(5): 3851-7[DOI][PubMed]
  • 17. Abouzeid HE, Kassem AM, Abdel Wahab AH, El-mezayen HA, Sharad H, Abdel Rahman S. Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors. Tumour Biol. 2011; 32(5): 845-52[DOI][PubMed]
  • 18. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 2013; 5(2): 676-713[DOI][PubMed]
  • 19. Mokarram P, Naghibalhossaini F, Saberi Firoozi M, Hosseini SV, Izadpanah A, Salahi H, et al. Methylenetetrahydrofolate reductase C677T genotype affects promoter methylation of tumor-specific genes in sporadic colorectal cancer through an interaction with folate/vitamin B12 status. World J Gastroenterol. 2008; 14(23): 3662-71[PubMed]
  • 20. Kisiel JB, Yab TC, Taylor WR, Simonson JA, Garrity Park M, Hussain FTN. Stool DNA Methylation Markers for the Detection of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease. Gastroenterol . 2012; 142(5)
  • 21. Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer. 2005; 104(10): 2035-47[DOI][PubMed]
  • 22. Wang X, Kuang YY, Hu XT. Advances in epigenetic biomarker research in colorectal cancer. World J Gastroenterol. 2014; 20(15): 4276-87[DOI][PubMed]
  • 23. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest. 2004; 84(7): 884-93[DOI][PubMed]
  • 24. Psofaki V, Kalogera C, Tzambouras N, Stephanou D, Tsianos E, Seferiadis K, et al. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas. World J Gastroenterol. 2010; 16(28): 3553-60[PubMed]
  • 25. Kycler W, Szarzynska B, Lozinski C, Korski K, Lamperska K. Analysis of O6-methylguanine-DNA methyltransferase methylation status in sporadic colon polyps. Rep Pract Oncol Radiother. 2012; 17(1): 13-8[DOI][PubMed]
  • 26. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res. 2001; 61(3): 827-30[PubMed]
  • 27. Huang ZH, Li LH, Yang F, Wang JF. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 2007; 13(6): 950-4[PubMed]
  • 28. Oberwalder M, Zitt M, Wontner C, Fiegl H, Goebel G, Zitt M, et al. SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis. 2008; 23(1): 15-9[DOI][PubMed]
  • 29. Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E, et al. Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama. 2011; 65(3): 169-77[PubMed]
  • 30. Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer. 2000; 36(18): 2294-300[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments